๐ฐ Laboratory Abnormalities News
Page 2 - Laboratory Abnormalities News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Laboratory Abnormalities. Real-time updates on events, politics, business and more.
May 11, 2023
/PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at...
May 11, 2023
First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of... | May 11, 2023
May 11, 2023
11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant ...
March 28, 2023
Sotyktu demonstrated superior efficacy in improving skin clearance over placebo and twice-daily Otezla® , with a well-tolerated safety profile, in the pivotal Phase 3 POETYK PSO clinical... | March 28, 2023
March 14, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for...
February 13, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology...
September 16, 2022
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab In RELATIVITY-047, Opdualag more than
September 10, 2022
Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...
September 10, 2022
  Bristol Myers Squibbโs Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 yearsPivotal Phase 3 POETYK PSO clinical trials demonstrate...
September 5, 2022
05.09.2022 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across several solid tumors showcasing the breadth of the Companyโs oncology development program at the European Society for Medical Oncology (ESMO) Congress ...